Search

Your search keyword '"Chu, Felix"' showing total 197 results

Search Constraints

Start Over You searched for: Author "Chu, Felix" Remove constraint Author: "Chu, Felix"
197 results on '"Chu, Felix"'

Search Results

1. Ubiquitin ligase COP1 coordinates transcriptional programs that control cell type specification in the developing mouse brain

2. Non-progressing cancer patients have persistent B cell responses expressing shared antibody paratopes that target public tumor antigens

3. Interviewing in Educational Research: A Bibliographic Essay.

4. Supplementary Figure 5 from The Selective PI3K Inhibitor XL147 (SAR245408) Inhibits Tumor Growth and Survival and Potentiates the Activity of Chemotherapeutic Agents in Preclinical Tumor Models

5. Supplementary Figure 3 from The Selective PI3K Inhibitor XL147 (SAR245408) Inhibits Tumor Growth and Survival and Potentiates the Activity of Chemotherapeutic Agents in Preclinical Tumor Models

6. Supplementary Figure 6 from The Selective PI3K Inhibitor XL147 (SAR245408) Inhibits Tumor Growth and Survival and Potentiates the Activity of Chemotherapeutic Agents in Preclinical Tumor Models

7. Supplementary Figure Legends and Supplementary Tables 1 through 3 from Characterization of the Activity of the PI3K/mTOR Inhibitor XL765 (SAR245409) in Tumor Models with Diverse Genetic Alterations Affecting the PI3K Pathway

10. Data from Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth

11. Supplementary Figure 1 from The Selective PI3K Inhibitor XL147 (SAR245408) Inhibits Tumor Growth and Survival and Potentiates the Activity of Chemotherapeutic Agents in Preclinical Tumor Models

12. Supplementary Figures 1 through 5 from Characterization of the Activity of the PI3K/mTOR Inhibitor XL765 (SAR245409) in Tumor Models with Diverse Genetic Alterations Affecting the PI3K Pathway

13. Supplementary Tables 1 - 3, Figure 1 from Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth

14. Data from The Selective PI3K Inhibitor XL147 (SAR245408) Inhibits Tumor Growth and Survival and Potentiates the Activity of Chemotherapeutic Agents in Preclinical Tumor Models

15. Supplementary Figure 4 from The Selective PI3K Inhibitor XL147 (SAR245408) Inhibits Tumor Growth and Survival and Potentiates the Activity of Chemotherapeutic Agents in Preclinical Tumor Models

16. Supplementary Figure Legends, Tables 1 - 6 from The Selective PI3K Inhibitor XL147 (SAR245408) Inhibits Tumor Growth and Survival and Potentiates the Activity of Chemotherapeutic Agents in Preclinical Tumor Models

17. Supplementary Figure 2 from The Selective PI3K Inhibitor XL147 (SAR245408) Inhibits Tumor Growth and Survival and Potentiates the Activity of Chemotherapeutic Agents in Preclinical Tumor Models

18. Technocracy or transformation? Mapping women's policy agencies and orienting gender (in)equality in the Canadian provinces

19. Librarian-Faculty Relations in Collection Development.

20. Framing Reference Encounters.

21. Collaboration in a Loosely Coupled System: Librarian-Faculty Relations in Collection Development.

22. Reference Service and Bounded Rationality: Helping Students with Research.

23. Bibliographic Instruction and the Scholarship of Integration.

24. Evaluating the Skills of the Systems Librarian.

26. 689 ATRC-101 Drives Potent Single-Agent Activity in Mouse Syngeneic Tumor Models via a Novel Cellular Mechanism of Action

27. 469 Cooperation between checkpoint inhibitors targeting the PD-1/PD-L1 axis and ATRC-101, a novel clinical-stage candidate for the treatment of solid tissue malignancies

28. Generation and characterization of a unique reagent that recognizes a panel of recombinant human monoclonal antibody therapeutics in the presence of endogenous human IgG

30. Abstract 1543: Discovery of antibodies for ADC therapy from cancer patients who show durable clinical response to checkpoint inhibitors

31. Abstract 3966: Mining the cancer immuno-responsome: The identification of functional antitumor antibodies from patients receiving checkpoint inhibitors

32. Anti-tumor immune responses in metastatic breast cancer exceptional responder patients.

33. Impact on immune effectors of anti-tumor antibodies isolated from cancer patients.

38. Bridging the LIS-practitioner gap: some frames for research

40. Social aspects of information

41. Librarian-faculty relations in collection development.

44. The Selective PI3K Inhibitor XL147 (SAR245408) Inhibits Tumor Growth and Survival and Potentiates the Activity of Chemotherapeutic Agents in Preclinical Tumor Models

47. Characterization of the Activity of the PI3K/mTOR Inhibitor XL765 (SAR245409) in Tumor Models with Diverse Genetic Alterations Affecting the PI3K Pathway

48. In Vitro and In Vivo Activity of Cabozantinib (XL184), an Inhibitor of RET, MET, and VEGFR2, in a Model of Medullary Thyroid Cancer

50. Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth

Catalog

Books, media, physical & digital resources